Fixation of pharmaceuticals on graphene surfaces

药物在石墨烯表面的固定

• 批准号: 470387051
• 负责人: Professor Dr. Siegfried Eigler
• 金额: --
• 依托单位: Institut de Biologie Moléculaire et Cellulaire (IBMC)
• 依托单位国家: 德国
• 项目类别: Research Grants
• 资助国家: 德国
• 项目状态: 未结题
• 来源: https://gepris.dfg.de/gepris/projekt/470387051?language=en
• 关键词: Fixation; pharmaceuticals; graphene; surfaces

In a current joint project, the applicants were able to show that arylazocarboxylic acid esters are suitable for a novel, defect selective functionalization of graphene. In this research project, further aryl radical sources under various reaction conditions are to be considered with regard to selectivity in graphene functionalization. In the second section, the newly developed functionalization reactions will be used to link cleavable linkers to the graphene surface. Thereby a fluorescent dye is attached to enable the model study of the targeted release of bound compounds. The studies are performed on both surface bound graphene and dissolved graphene derivatives. Finally, the collected results will be used for the binding of drugs on the graphene surface, whereat in the case of covalent binding, a triggered release will be enabled by the cleavable linkers. The above mentioned selectivity in graphene functionalization, which is based on the use of various aryl radical precursors, will in particular be employed to attach cytostatic drugs in combination with polyethylene glycol derivatives to graphene. In this way, not only water solubility and cancer cell targeting can be improved, but it is further possible to significantly reduce the otherwise observed toxicity of graphene. In summary, the aryl radical based, selective functionalization of graphene thus enables the development of novel, medicinally applicable carrier systems, which can overcome the yet known drawbacks of graphene as carrier material. To aim at medicinal application, the graphene conjugates prepared within the research project will be continuously – and in the final stage intensively –evaluated regarding their biomedical properties.

在当前的联合项目中，申请人能够证明芳基偶氮羧酸酯适用于石墨烯的新型缺陷选择性官能化。在该研究项目中，在各种反应条件下的进一步芳基自由基源被认为是关于石墨烯官能化的选择性。在第二部分中，新开发的官能化反应将用于将可裂解的连接体连接到石墨烯表面。因此，荧光染料被连接以使得能够进行结合化合物的靶向释放的模型研究。对表面结合的石墨烯和溶解的石墨烯衍生物进行研究。最后，收集的结果将用于石墨烯表面上的药物结合，在共价结合的情况下，通过可裂解的连接体将能够触发释放。上述石墨烯功能化的选择性基于使用各种芳基前体，将特别用于将细胞抑制药物与聚乙二醇衍生物组合连接到石墨烯上。通过这种方式，不仅可以改善水溶性和癌细胞靶向，而且还可以显著降低石墨烯的毒性。总之，石墨烯的基于芳基的选择性官能化因此使得能够开发新型的可药用载体系统，其可以克服石墨烯作为载体材料的已知缺点。为了达到医学应用的目的，在研究项目中制备的石墨烯共轭物将持续进行-并在最后阶段集中评估-其生物医学特性。